Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial

BACKGROUND: Aging frailty, characterized by decreased physical and immunological functioning, is associated with stem cell depletion. Human allogeneic mesenchymal stem cells (allo-hMSCs) exert immunomodulatory effects and promote tissue repair. METHODS: This is a randomized, double-blinded, dose-fin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gerontol A Biol Sci Med Sci
Autors principals: Tompkins, Bryon A, DiFede, Darcy L, Khan, Aisha, Landin, Ana Marie, Schulman, Ivonne Hernandez, Pujol, Marietsy V, Heldman, Alan W, Miki, Roberto, Goldschmidt-Clermont, Pascal J, Goldstein, Bradley J, Mushtaq, Muzammil, Levis-Dusseau, Silvina, Byrnes, John J, Lowery, Maureen, Natsumeda, Makoto, Delgado, Cindy, Saltzman, Russell, Vidro-Casiano, Mayra, Da Fonseca, Moisaniel, Golpanian, Samuel, Premer, Courtney, Medina, Audrey, Valasaki, Krystalenia, Florea, Victoria, Anderson, Erica, El-Khorazaty, Jill, Mendizabal, Adam, Green, Geoff, Oliva, Anthony A, Hare, Joshua M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
The Journal of Gerontology: Translational Articles: Stem Cell Transplantation for Frailty
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5861900/
https://ncbi.nlm.nih.gov/pubmed/28977399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/gerona/glx137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars